Somatic Tumour Profiling

OmniSeq INSIGHT

Make confident treatment decisions based on the entire tumour profile 

From a single tumour biopsy, analyzed by advanced NGS technology, OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report. The patient report delivers complete INSIGHT into the tumor and its microenvironment by summarizing FDA-approved therapies, immunotherapies and eligible clinical trials for your patient’s solid tumour.  This is a "Pan Cancer" panel and can be performed on ANY solid tumour. This treatment is performed on a small FFPE sample. 

A consolidated assay for two different treatment paradigms:

Genomic profiling:

• 523 gene NGS panel
• MSl and TMB*
• DNA and RNA sequencing
• SNVs, indels, CNAs and fusions*
• Interrogation of fuII coding regions 

Immune profiling

• PD-L1 immunohistochemistry (IHC)
• 64 RNA expression/immune profiling genes by immune cycle step:
• T-cell priming/trafficking
• T-cell recognition
• T-cell infiltration
• Killing cancer cells
• Cancer testis antigens

INSIGHT is the only comprehensive test to contain all of the following:

• Genes aligned with FDA approvals, professional practice guidelines and clinical trials
• HRR/HRD-related* genes for PARP therapeutic selection
• Full coding region coverage for each gene which improves variant detection compared to “hotspot” testing strategies
• An RNA-seq hybrid capture approach which allows for the detection of common and novel fusions
• Targeting of unique emerging and actionable markers
• Immune gene expression (mRNA) analysis to evaluate the interaction between the tumour and its microenvironment

INSIGHT may be useful as a tool in various clinical settings, including:

• When guidelines recommend broad genomic profiling to evaluate genes with clinical evidence and therapeutic  recommendations or when standard biomarker evaluation yields no targeted therapeutic option
• When a broad genomic profile identifies treatment options in clinical trials including immunotherapies and targeted therapies for patient enrollment
• When a cancer lacks an effective standard-of-care therapy at the time of diagnosis or when a tumour is poorly differentiated and of uncertain origin
• When relapse or disease progression has occurred prior therapies

*GEP - genomic expression profiling
Data as of June 16, 2021

OmniSeq High Laboratory Quality Standards

• NYS CLEP approved
• ISO 13485 (2016) certified
• CLIA and CAP accredited

Ressources

• Download OmniSeq Insight Brochure
• Download OmniSeq Insight Gene List
• Download OmniSeq Insight Requisition
• Download OmniSeq Insight Payment Authorization Form
• Download OmniSeq Specimen Instructions and Packing Sheet